
Akums Drugs & Pharmaceuticals IPO
- Issue price
- ₹679
- Listing price
- ₹725
- +6.77%
- Current price
- ₹741.05
- +9.14%
- Subscribed
- 63.44x
- Issue size
- ₹1,856.74 Cr
- Listed on
- 6 Aug 2024
IPO timeline
- Opens30 JulTue
- Closes1 AugThu
- Allotment2 AugFri
- Refunds5 AugMon
- Demat credit5 AugMon
- Listing6 AugTue
Issue details
- Price band
- ₹646 – ₹679 per share
- Issue size
- ₹1,856.74 Cr
- Fresh issue
- Not available
- Offer for sale
- Not available
- Issue type
- Fresh capital cum OFS
- Face value
- ₹2 per share
- Lot size
- 22 shares
- Minimum investment
- ₹14,938
- Listing on
- BSE, NSE
- Exchange code
- AKUMS · 544222
This issue combines a fresh issue and an offer for sale. The amounts for each part are not available in our data; see the offer document for the split.
Lot size and investment
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 22 | ₹14,938 |
| Retail (Max) | 13 | 286 | ₹1,94,194 |
| S-HNI (Min) | 14 | 308 | ₹2,09,132 |
| B-HNI (Min) | 67 | 1,474 | ₹10,00,846 |
Reservation
- QIB
- 2,03,43,188 shares (75.00% of the Offer)
- NII
- 40,68,637 shares (15.00% of the Offer)
- Retail
- 27,12,424 shares (10.00% of the Offer)
- Employee
- 2,43,902 shares (0.89% of the Offer)
Allotment status
The allotment for this IPO is final. Check whether you received shares on the registrar's website using your PAN, application number or demat account (DP / Client ID).
Check allotment on MUFG Intime India- 1Open the registrar's allotment page and select this IPO from the list.
- 2Enter your PAN, application number or DP / Client ID.
- 3Submit to see the number of shares allotted, if any.
- Basis of allotment
- 2 Aug 2024
- Refunds initiated
- 5 Aug 2024
- Shares credited to demat
- 5 Aug 2024
- Listing
- 6 Aug 2024
Grey market premium (GMP)
- Current GMP
- ₹40
- +6.00%
- Estimated listing price
- ₹719
- Issue price ₹679
- Highest
- ₹195
- 30 Jul
- Lowest
- ₹40
- 5 Aug
GMP by day (₹ per share)
Day-wise GMP table
| Date | GMP | Premium | Est. listing |
|---|---|---|---|
| 6 Aug 2024 | ₹40 | +6.00% | ₹719 |
| 5 Aug 2024 | ₹40 | +6.00% | ₹719 |
| 4 Aug 2024 | ₹80 | +12.00% | ₹759 |
| 3 Aug 2024 | ₹90 | +13.00% | ₹769 |
| 2 Aug 2024 | ₹120 | +18.00% | ₹799 |
| 1 Aug 2024 | ₹130 | +19.00% | ₹809 |
| 31 Jul 2024 | ₹168 | +25.00% | ₹847 |
| 30 Jul 2024 | ₹195 | +29.00% | ₹874 |
- Kostak rate
- ₹0
GMP is an unofficial indicator from an unregulated market. It is shown for information only and is not a prediction of the listing price or a recommendation to apply.
Subscription status
- QIB90.09x
- NII (HNI)42.1x
- Retail20.8x
- Employee4.14x
Financials
- P/E Ratio
- 13580
- EPS (₹)
- 0.05
- RoE
- 0.11%
- RoCE
- 3.37%
- RoNW
- -0.57%
- PAT Margin
- 0.02%
- EBITDA Margin
- 3.73%
- Debt / Equity
- 0.69
- NAV (₹)
- 49.59
Separate pre- and post-issue P/E are not available for this IPO; the P/E shown is as disclosed for the issue.
| Period ended | 31 Mar 2024 | 31 Mar 2023 | 31 Mar 2022 |
|---|---|---|---|
| Assets | 3,516.37 | 3,266.53 | 3,069.05 |
| Total Income | 4,212.21 | 3,700.93 | 3,694.52 |
| Profit After Tax | 0.79 | 97.82 | -250.87 |
| NET Worth | 709.50 | 717.19 | 621.98 |
| Total Borrowing | 491.56 | 536.97 | 357.95 |
Peer comparison
| Company | Issue size | P/E | RoNW | PAT margin | Subscribed | Listing gain |
|---|---|---|---|---|---|---|
| Akums Drugs & Pharmaceuticals This IPO | ₹1,856.74 Cr | 13580 | -0.57% | 0.02% | 63.44x | +6.77% |
| Indegene Mainboard · listed 13 May 2024 | ₹1,841.76 Cr | 33.53 | 18.23% | 12.62% | 70.3x | +44.91% |
| Symbiotec Pharmalab Mainboard · listed 1 Sep 2026 | ₹1,757 Cr | 56.81 | 9.48% | 12.60% | 71.26x | 0.00% |
| Sagility India Mainboard · listed 12 Nov 2024 | ₹2,106.4 Cr | 61.52 | 0.29% | 11.83% | 3.2x | +3.53% |
| Entero Healthcare Solutions Mainboard · listed 16 Feb 2024 | ₹1,600 Cr | 129.75 | -1.86% | 4.69% | 1.56x | -2.33% |
| Paras Healthcare Mainboard · listed 28 Oct 2026 | ₹1,450 Cr | 37.72 | 11.83% | 10.38% | 2.23x | +3.90% |
| Inventurus Knowledge Solutions Mainboard · listed 19 Dec 2024 | ₹2,497.92 Cr | 54.66 | 32% | 20.38% | 52.68x | +42.96% |
Peers are other recent IPOs from the same industry, closest in issue size. Ratios are as disclosed at the time of each issue. This is not the listed-peer table from the offer document.
IPO objectives
How Akums Drugs & Pharmaceuticals plans to use the money raised, as stated in the offer document.
- Repayment/prepayment of all or certain borrowings of our Company₹159.91 Cr
- Repayment/prepayment of all or certain borrowings of our Subsidiaries namely, Maxcure Nutravedics Limited and Pure and Cure Healthcare Private Limited₹227.09 Cr
- Funding incremental working capital requirements of our Company₹55 Cr
- Pursuing inorganic growth initiatives through acquisitions₹27.87 Cr
- General corporate purposes₹167.5 Cr
About Akums Drugs & Pharmaceuticals
Akums Drugs and Pharmaceuticals Limited was incorporated on 19 April 2004. It is a pharmaceutical contract development and manufacturing organisation (CDMO) offering products and services in India and overseas. It also sells branded pharmaceutical formulations and makes active pharmaceutical ingredients. Its other services include formulation R&D, preparing and filing regulatory dossiers, and testing. Some of its units are accredited by global agencies such as European GMP, WHO GMP and the US National Sanitation Foundation. Its promoters are Sanjeev Jain, Sandeep Jain and Akums Master Trust. The IPO was Rs 1,856.74 crore, with Rs 680.99 crore of fresh issue and Rs 1,175.75 crore of offer for sale, mostly by investors, with the two individual promoters also selling. Rs 387.00 crore was planned for repaying borrowings of the company and its subsidiaries.
Strengths
- Total income rose from Rs 3,694.52 crore in FY2022 to Rs 4,212.21 crore in FY2024.
- Rs 680.99 crore of the issue was fresh capital, with Rs 387.00 crore for repaying debt.
- Some units carry European GMP and WHO GMP accreditation, and total income was Rs 3,700.93 crore in FY2023.
- Total borrowing fell from Rs 536.97 crore on 31 March 2023 to Rs 491.56 crore on 31 March 2024.
- Net worth was Rs 709.50 crore on 31 March 2024.
Risks
- Profit was almost nil, at Rs 0.79 crore in FY2024, and the source puts the PAT margin at 0.02%.
- The company made a loss of Rs 250.87 crore in FY2022.
- The pre-issue P/E was 13580 at the upper band of Rs 679, based on EPS of Rs 0.05.
- Rs 1,175.75 crore of the issue was offer for sale, and CDMO income depends on client orders.
- Promoters and the promoter group held 82.48% before the issue and 75.29% after it.
Promoters and shareholding
Sanjeev Jain, Sandeep Jain and Akums Master Trust
- Promoter holding, pre-issue
- 82.48%
- Promoter holding, post-issue
- 75.29%
Anchor investors
Registrar, lead managers and documents
Documents
Akums Drugs & Pharmaceuticals IPO: common questions
1.When does the Akums Drugs & Pharmaceuticals IPO open and close?
The Akums Drugs & Pharmaceuticals IPO opens on 30 Jul 2024 and closes on 1 Aug 2024.
2.What is the price band of the Akums Drugs & Pharmaceuticals IPO?
The price band is ₹646 – ₹679 per share, with a lot size of 22 shares and a minimum investment of ₹14,938.
3.What is the size of the Akums Drugs & Pharmaceuticals IPO?
The issue size is ₹1,856.74 Cr (Fresh capital cum OFS).
4.What is the GMP of the Akums Drugs & Pharmaceuticals IPO?
The last reported grey market premium is ₹40 per share as of 06 Aug 2024, 12:00 PM IST. GMP is unofficial and changes frequently.
5.When is the Akums Drugs & Pharmaceuticals IPO allotment?
The basis of allotment is expected on 2 Aug 2024. Allotment status can be checked with the registrar, MUFG Intime India Private Limited.
6.When will the Akums Drugs & Pharmaceuticals IPO list?
The shares listed on 6 Aug 2024 on BSE, NSE.
7.Who is the lead manager of the Akums Drugs & Pharmaceuticals IPO?
The book running lead managers are Axis Capital, ICICI Securities, Ambit Capital, Citigroup Global Markets India Pvt. Ltd, and the registrar is MUFG Intime India Private Limited.
8.What will the money raised in the Akums Drugs & Pharmaceuticals IPO be used for?
As stated in the offer document, the proceeds are for: Repayment/prepayment of all or certain borrowings of our Company; Repayment/prepayment of all or certain borrowings of our Subsidiaries namely, Maxcure Nutravedics Limited and Pure and Cure Healthcare Private Limited; Funding incremental working capital requirements of our Company; Pursuing inorganic growth initiatives through acquisitions; General corporate purposes.
9.How can my company launch an IPO like Akums Drugs & Pharmaceuticals?
Start with an IPO readiness assessment: eligibility for the Main Board, audited financials, governance, conversion to a public limited company and an indicative valuation. Be IPO Ready advises promoters through each step, from readiness to listing day.
For business owners
Your company could be the next listing
Businesses like these raise growth capital on the public markets every week. Tell us about yours and our advisors will tell you, plainly, whether an IPO is within reach and what it would take.
- Eligibility check against NSE Emerge, BSE SME and Main Board norms
- Indicative valuation and issue size for your business
- A clear timeline from readiness to listing day
Check if your business can list
Fill in the eligibility form and get an assessment of where you stand. It takes about five minutes.
Prefer to talk? Call +91 92130 20393